Equibles does not estimate personal net worth.
Get an email with a short summary when Phathom Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get PHAT alertsSteve Basta is recorded as CEO at Phathom Pharmaceuticals, Inc. (PHAT). Steve Basta has spoken on 2 earnings calls and 1 other investor event across 1 company, most recently for Phathom Pharmaceuticals, Inc. on July 30, 2026. Phathom Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Phathom Pharmaceuticals, Inc. includes Steven Basta (CEO and Board Member), Steven L. Basta (CEO and Board Member), Anthony Guzzo (CFO and Chief Accounting Officer) and 7 others.
“Let me start by highlighting the significant transition Fathom has made over the last year and a half. I'm very proud to share that for the first time in Fathom's history and ahead of our guidance, we generated positive operating profit in Q2, excluding stock-based compensation.”
“Paul, thanks so much for the invitation to be here. It's a pleasure. Just a really high-level overview of the company, what we've done over the past year and where we're headed this year, so Fathom has commercialized Bequesna, which is the first-to-market PCAB to treat gastroesophageal reflux.”
“And thank you to everyone joining us today. I'll start with an overview of our financial and commercial highlights this quarter and then provide commentary on our shift to a greater gastroenterology focus and our current operating priorities.”
Biotechnology · Healthcare
CEO
